March 15, 1991Annals of Internal Medicine
Sudden Cardiac Death: Management of High-Risk Patients
Population
Survivors of sudden cardiac death
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
Supports avoiding empiric antiarrhythmics in SCD survivors; leaves open comparative effectiveness versus contemporary ICDs and ablation.
Key Points
- To review the underlying pathophysiology of sudden cardiac death and delineate comprehensive clinical management protocols for high-risk survivors.
- Synthesized clinical literature detailing chronic arrhythmogenic substrates, notably myocardial fibrosis and left ventricular dysfunction resulting from prior infarction.
- Evaluated diagnostic pathways, incorporating coronary angiography, wall-motion assessment, and programmed ventricular stimulation via serial electrophysiologic studies.
- Sudden cardiac death results primarily from the interaction between chronic structural substrates and acute electrical, ischemic, or neurohormonal triggers.
- Empiric antiarrhythmic drug therapy yields no demonstrable survival benefit compared with therapies directed by programmed ventricular stimulation.
- Effective secondary prevention necessitates correcting reversible triggers alongside definitive substrate-modifying therapies, including surgical arrhythmia ablation and implantable cardioverter-defibrillators.
Structured PICO
P
Population
Survivors of sudden cardiac death
I
Intervention
Comprehensive cardiovascular and electrophysiologic evaluation, management of reversible triggers, EP-guided antiarrhythmic therapy, surgical suppression, or ICD implantation
Management of sudden cardiac death survivors should focus on identifying and correcting triggers and substrates, utilizing EP-guided pharmacologic therapy or ICDs rather than empiric antiarrhythmics.
Cite This Study
Akhtar et al. (1991) studied this question.